Q-omics provides the consensus-scored MTND6P8 profile across patient tissues and cancer cell-line models. MTND6P8 expression is associated with patient survival in 8 of 34 cancer types, with the highest sampling consensus in PAAD. Among the 18 cancer types available for tumor–normal comparison, MTND6P8 is differentially expressed in 1, with the highest sampling consensus in ESCA. Additionally, MTND6P8 RNA expression shows 4,512 significant gene co-expression associations, with the highest sampling consensus in THCA. Together, these results highlight PAAD, ESCA, and THCA as cancer lineages where MTND6P8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MTND6P8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MTND6P8 survival associations across molecular data types. MTND6P8 RNA expression shows survival associations in the most cancer types (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MTND6P8 RNA expression–survival associations across cancer types. High MTND6P8 expression shows unfavorable associations in PAAD, LUAD, STAD, SARC, GBM and COAD. The PAAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify PAAD as the clearest survival context for MTND6P8 RNA expression.
This table summarizes MTND6P8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in ESCA for RNA.
This table ranks reproducible tumor–normal expression differences for MTND6P8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MTND6P8 shows lower tumor expression in ESCA. The ESCA box plot shows higher MTND6P8 RNA expression in normal versus tumor tissue (log2 FC = −0.074, t-test p = .040).
This table shows molecular features associated with MTND6P8 in patient tissues and cancer cell lines. In patient samples, MTND6P8 shows the broadest associations at the RNA and protein expression levels, with THCA recurring as the lineage with the largest associated feature set.
